Steven Cohen Ultragenyx Pharmaceutical Inc. Transaction History
Point72 Asset Management, L.P.
- $40.1 Billion
- Q1 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 976,052 shares of RARE stock, worth $33.2 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
976,052
Previous 1,182,877
17.48%
Holding current value
$33.2 Million
Previous $49.8 Million
28.98%
% of portfolio
0.09%
Previous 0.12%
Shares
29 transactions
Others Institutions Holding RARE
# of Institutions
336Shares Held
88.9MCall Options Held
1.08MPut Options Held
1.04M-
Vanguard Group Inc Valley Forge, PA10MShares$340 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$191 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.16MShares$142 Million0.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.22MShares$110 Million0.01% of portfolio
-
State Street Corp Boston, MA2.62MShares$89.1 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.38B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...